MLTX vs ARQT

Analysts rate MoonLake Immunotherapeutics (MLTX) a "Buy" — based on 18 analyst ratings — the highest consensus in this comparison.

The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

Over the past 5 years, MoonLake Immunotherapeutics (MLTX) delivered a total return of +68.

6%, compared to -39. 5% for Arcutis Biotherapeutics, Inc. (ARQT). Over 10 years, the gap is even starker: MLTX returned +64. 0% versus ARQT's -5. 2%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

By beta (market sensitivity over 5 years), MoonLake Immunotherapeutics (MLTX) is the lower-risk stock at 1.

17β versus Arcutis Biotherapeutics, Inc. 's 1. 48β — meaning ARQT is approximately 26% more volatile than MLTX relative to the S&P 500. On balance sheet safety, Arcutis Biotherapeutics, Inc. (ARQT) carries a lower debt/equity ratio of 3% versus 25% for MoonLake Immunotherapeutics — giving it more financial flexibility in a downturn.

On earnings-per-share growth, the picture is similar: Arcutis Biotherapeutics, Inc.

grew EPS 88. 8% year-over-year, compared to -86. 8% for MoonLake Immunotherapeutics. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.

MoonLake Immunotherapeutics (MLTX) is the more profitable company, earning 0.

0% net margin versus -4. 3% for Arcutis Biotherapeutics, Inc. — meaning it keeps 0. 0% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: MLTX leads at 0. 0% versus -3. 3% for ARQT. At the gross margin level — before operating expenses — ARQT leads at 90. 2%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

Analyst consensus price targets imply the most upside for ARQT: 71.

8% to $35. 50.

None of the stocks in this comparison currently pay a material dividend.

All are effectively zero-yield and should be held for capital appreciation rather than income.

For long-horizon retirement investors, MoonLake Immunotherapeutics (MLTX) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 1.

17)). Both have compounded well over 10 years (MLTX: +64. 0%, ARQT: -5. 2%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.

In terms of investment character: MLTX is a small-cap quality compounder stock; ARQT is a small-cap high-growth stock. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.